Repros Receives Official FDA Minutes From Type C Meeting Held on 12/13/11 Confirming Path Forward for Androxal

Repros Therapeutics Inc.^

today announced the Company has received the official FDA minutes from its recent Type C meeting held with the joint divisions of urologic and endocrinologic products. The Company believes the meeting and minutes will help it set the path forward for Androxal. As part of the request for the meeting, Repros asked three questions. The first two dealt with whether or not either the Endocrine or Urology Division would allow the normalization of testicular testosterone synthesis as the only primary endpoint needed for approval. In the third question Repros asked if it was appropriate for both divisions to review the dossier.